Applying New EU Guideline Updates in AML: Best Practice in Treatment and Molecular Testing - Spain

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Date and Time: Thursday, 27 October, 2022 from 9.00 - 10.30 CET

  • Welcome and Introduction
  • Importance of molecular testing in AML and practical considerations for clinical practice
  • Overview of new and revised European LeukemiaNet Working Party guidelines
  • Treatment options for the most common targetable biomarkers for AML: FLT3, IDH1, and IDH2
  • Coordinating testing, treatment, adverse event management and monitoring for progression
  • Panel discussion: Putting guidelines into clinical practice
  • Audience Question and Answer


Program Director
Adolfo de la Fuente Burguera, MD

Director, Hematology Department
Hospital MD Anderson Cancer Center
Madrid, Spain

Claudio Cerchione, MD, PhD

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS

Naval G. Daver, MD

Leukemia Research Alliance Program
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Pau Montesinos, MD

Hematology Department
Hospital Universitari i Politècnic La Fe
Avinguda Fernando Abril Martorell, 106
València, Spain

This educational activity is not certified for CME/CE credit.

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.

Target Audience
This educational program is intended for specialty physicians, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with AML.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Develop genetic testing strategies that incorporate best communication techniques and expert guidance for all patient subgroups with AML that may benefit from targeted therapy
  • Describe to patients and colleagues key impactful updates in the European LeukemiaNet Working Party guidelines based on recent data that optimize outcomes for patients with AML
  • Characterize the pathophysiologic, clinical, cytogenetic, and molecular profiles that guide therapy selection for patients with AML
  • Develop personalized treatment plans for therapeutically targetable molecular subsets of AML


This educational activity is not certified for CME/CE credit.